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Background-Aims. Early prediction of the severity of acute pancreatitis would lead to prompt intensive treatment resulting in
improvement of the outcome. The present study investigated the use of C-reactive protein (CRP), interleukin IL-8 and tumor
necrosis factor-α (TNF-α) as prognosticators of the severity of the disease. Methods. Twenty-six patients with acute pancreatitis
were studied. Patients with APACHE II score of 9 or more formed the severe group, while the mild group consisted of patients with
APACHE II score of less than 9. Serum samples for measurement of CRP, IL-8 and TNF-α were collected on the day of admission
and additionally on the 2nd, 3rd and 7th days. Results. Signiﬁcantly higher levels of IL-8 were found in patients with severe acute
pancreatitis compared to those with mild disease especially at the 2nd and 3rd days (P = .001 and P = .014, resp.). No signiﬁcant
diﬀerence for CRP and TNF-α was observed between the two groups. The optimal cut-oﬀs for IL-8 in order to discriminate severe
from mild disease at the 2nd and 3rd days were 25.4pg/mL and 14.5pg/mL, respectively. Conclusions. IL-8 in early phase of acute
pancreatitis is superior marker compared to CRP and TNF-α for distinguishing patients with severe disease.
Copyright © 2009 Michael K. Digalakis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Acute pancreatitis remains a common disease in western
societies and in most cases it resolves spontaneously with
supportive treatment. Nevertheless, 25% of the patients
will develop local or systemic complications which may
require surgical intervention. The most crucial point is the
development of pancreatic necrosis, which often progresses
to a systemic inﬂammatory response syndrome (SIRS).
An approximate mortality of 10%–30% has been reported
in patients with severe forms of acute pancreatitis while
most deaths are attributed to sepsis and to multiple organ
dysfunction syndrome (MODS).
Staging the severity of acute pancreatitis based on clinical
parameters has limited speciﬁcity and sensitivity for the
prediction of adverse events. Already from the decade of
1980s staging using serum criteria was employed [1–3].
As an inﬂammatory process, acute pancreatitis results in
an excessive leukocyte activation and increased migration of
neutrophils to the inﬂamed area with a consequent release
of proinﬂammatorymediators including interleukins (IL-1b,
IL-6, IL-8, IL-10, IL-18) and Tumor Necrosis Factor-alpha
(TNF-α)[ 4–11]. These mediators have been involved with
the pathogenesis of progression of a pancreatic infection
to necrosis and consequently to SIRS and multiorgan
failure.
The detection of cytokines appears to provide a more
accurate and objective method for the assessment of the
severity of acute pancreatitis [4, 5, 8, 9, 11]. Many clinical
trials have employed the use of either cytokines [4, 5, 8,
9, 11] or serum amyloid A and procalcitonin [11–15]a s
prognosticators of the severity of acute pancreatitis.
Recent studies have suggested that the serum levels of
interleukins and TNF-α may be used to identify patients who
are prone to develop local or systemic complications and
were compared with CRP which has been employed in the
prediction of severity of acute pancreatitis [4, 7–11]. Early
identiﬁcation of such patients could lead to a more intensive
management that would result to a decreased morbidity and
mortality of that potentially fatal disease [4, 7–11].2 HPB Surgery
Table 1: Aetiology of acute pancreatitis (n = 26).
Aetiology Female (n = 11) Male (n = 15) Mild (n = 17) Severe (n = 9)
Gallstones 9 5 11 3
Alcohol 1 7 4 4
Other 1 3 2 2
The present study aimed to assess Interleukin-8 (IL-
8), C-reactive protein, and tumor necrosis factor-α as
prognosticators of a severe course of acute pancreatitis.
2. Patientsand Methods
Twenty-six patients who were admitted to hospital with the
diagnosis of acute pancreatitis were evaluated during the
second semester of 2007. These were 15 men and 11 women
with a mean age of 66 years. Patients with presentation
more than 24 hours from the onset of symptoms, pancreatic
tumor, prior pancreatic surgery, renal or hepatic failure,
trauma and diabetic ketoacidocis were excluded from the
study.
The diagnosis was based on the presenting signs and
symptoms (acute abdominal pain, vomiting, etc.), the
elevation of serum and urine amylase (>1000IU/L), and
the ﬁndings of the upper abdominal ultrasonography. The
conﬁrmation of diagnosis was made by Computed Tomog-
raphy with contrast within 72 hours from the time of the
admission.
AllpatientswereevaluatedaccordingtoAcutePhysiology
and Chronic Health Evaluation II (APACHE II) score deter-
mined within 48 hours of admission [16]. Those patients
with a score of 9 or more formed the severe group while
the rest formed the mild group. The identiﬁcation of the
aetiology of acute pancreatits was based on medical history
and on laboratory and imaging evaluation (Table 1).
Serum samples of both interleukin 8 (IL-8) C-reactive
protein and Tumor necrosis factor-α were collected on the
day of admission and additionally on the 2nd, 3rd, and
7 t hd a y sa n dt h e yw e r es t o r e da t−80◦C[ 5, 8]. Serum
levels of IL-8 and TNF-α were examined with enzyme-
linked immunosorbent assay (ELISA) using kits (Anibion,
Orgenium Laboratories, Finland). CRP was determined with
nephelometric technique (Dade Behring Inc).
IL-8, TNF-α, and CRP levels are presented as median
values (interquartile range). For the comparison of IL-8,
TNF-α, and CRP levels between the two groups Mann-
Whitney U test was used. IL-8, TNF-α, and CRP were
tested for their ability to discriminate between mild and
severe group using receiver operating characteristic (ROC)
curves. The overall performance of the ROC analysis was
quantiﬁed by computing area under the curve (AUC) and
95% conﬁdence intervals. An area of 1 indicated perfect
performance, while 0.5 indicated a performance that was not
diﬀerent than chance. Using ROC analysis were determined
the optimal sensitivity and speciﬁcity of using various cut-
oﬀ values for the discrimination between the two groups.
Sensitivity, speciﬁcity, positive and negative predictive values
are presented for the results of ROC analyses concerning
optimal cut-oﬀs. The reported P-values are two-tailed.
Statistical signiﬁcance was set at 0.05, and analysis was
conducted using STATA 7.0.
All the patients were closely followed according to the
Atlantacriteria[17],forthedevelopmentoflocal(pancreatic
collection, ascites, necrosis, and pseudocyst formation) or
systemic (ARDS, MODS, septic shock) complications and
managed accordingly (ERCP, CT-guided drainage, surgery).
3. Results
T h em e d i a nv a l u e so fI L - 8 ,T N F - α, and CRP levels from the
ﬁrst to the seventh days for the two groups are presented
in Table 2. The median value of IL-8 at the second day
was 53.2pg/mL (range: 37.8–61) for the severe group and
12.9pg/mL (range: 9.4–20) for the mild group, while the
median value of IL-8 at the third day was 37.3pg/mL (range:
25.1–60.6) for the severe group and 11.6pg/mL (range: 6.8–
19.2) for the mild one. IL-8 levels were signiﬁcantly greater
for severe group at the second and third day (P = .001 and
P = .014, resp.). TNF-α and CRP levels were not diﬀerent
between the two groups at any day, indicating no prognostic
ability to discriminate between the two groups. ROC analysis
was used for IL-8 in order to ﬁnd the optimal cut-oﬀ for
the discrimination of severe form mild group (Table 3). The
AUC for IL-8 at second and third day was 0.92 and 0.80,
respectively, (Figures 1 and 2). The optimal cut-oﬀ for IL-
8 in order to discriminate severe from mild disease at the
second day was 25.4pg/mL with sensitivity equal to 88.9%
and speciﬁcity equal to 88.2%. Additionally, the optimal cut-
oﬀ for IL-8 at the third day was 14.5pg/mL with sensitivity
equal to 88.9% and speciﬁcity equal to 55.8%.
4. Discussion
Interleukin-8 (IL-8) is one of the most important inﬂamma-
tory mediators in acute pancreatitis and other inﬂammatory
processes. IL-8 is released by many cell lines in the presence
of activated neutrophils [18–21]. It is also considered to be
one of the main secondary mediators of TNF-α induced
neutrophil activation [22]. On the other hand, TNF-α
which is a pleiotropic predominantly macrophage-derived
cytokine is thought to be involved in pathophysiological
responses in cases of severe injury or sepsis [20, 22]. C-
reactive protein (CRP) that is synthesized by the hepatocytes
is a nonspeciﬁc inﬂammatory marker routinely used in
assessment of severity of acute pancreatitis [18, 20, 22]. Its
synthesisisinducedbythereleaseofinterleukins1and6thus
a serum peak is usually delayed (>3rd day of onset of pain)
[18, 20, 22].HPB Surgery 3
Table 2: IL-8, TNF-α, and CRP levels for mild and severe groups.
IL-8 Mild (n = 17) Severe (n = 9)
Median (Int. range) Median (Int. range) P∗
1st day 24.5(10.3–37.5) 71(14.5–160) .124
2nd day 12.9(9.4–20) 53.2(37.8–61) .001
3rd day 11.6(6.8–19.2) 37.3(25.1–60.6) .014
7th day 11.5(5.1–22.2) 21.5(12.3–120) .063
TNF-alpha
TNF-α (1st day) 2(1–4.2) 2(1–11.3) .423
TNF-α (2nd day) 2(1–4.1) 1(1–10.5) .757
TNF-α (3rd day) 2(1–4.1) 1(1–24.5) .933
TNF-α (7th day) 2(1–4.1) 1(1–14.5) .609
CRP
CRP (1st day) 28.7(4.4–66) 30.5(18.6–36) .389
CRP (2nd day) 92.6(50.1–121) 119(107–170) .189
CRP (3rd day) 116(59.4–154) 161(144–196) .130
CRP (7th day) 23.9(6.5–87) 56(27–79) .305
∗ Mann-Whitney U test.
Table 3: Results from the ROC analysis of IL-8 for the discrimination between mild and severe groups.
AUC (95% CI) P Optimal cut-oﬀ Sensitivity % Speciﬁcity % PPV NPV
IL-8 (2nd day) 0.92(0.80–1.00) .001 25.4 88.9 88.2 80.0 93.8
IL-8 (3rd day) 0.80(0.58–1.00) .014 14.5 88.9 55.8 53.3 90.9
AUC: Area Under the Curve; CI: Conﬁdence Intervals; PPV: Positive Predictive Value; NPV: Negative Predictive Value.
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Figure 1: ROC curve for the discrimination between mild and
severe groups from IL-8 at second day.
Acute pancreatitis, regardless its aetiology, leads to the
disruption of the normal stimulation-secretion axis within
the pancreatic acinar cell. This ultimately triggers a pre-
mature enzyme activation system (concerning mainly the
metabolism of trypsinogen to trypsin) and a consequent
cascadeofcoactivationofotherpancreaticproenzymes(such
asproelastase, chymotrypsinogen, procarboxypeptidase, and
phosholipase A2), causing autodigestion of the gland [18,
19, 22, 23]. Blood monocytes and neutrophiles migrate to
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Figure 2: ROC curve for the discrimination between mild and
severe groups from IL-8 at third day.
the site of inﬂammation and secrete inﬂammatory mediators
[18].
In cases of acute pancreatitis with limited extent of
injury, spontaneous resolution of the inﬂammation occurs.
When inﬂammation persists, mediators are released to the
circulation leading to the malfunction of various organs and
a systematic inﬂammatory response (SIRS) [18, 19, 23]. This
progression from acute pancreatic inﬂammation to SIRS and
MODS may often be fulminant as approximately 50–60%4 HPB Surgery
of severe acute pancreatitis deaths occur within the ﬁrst
week [18, 20]. This systemic reaction combined with local
complications such as ﬂuid collection, haemorrhage, and
necrosis necessitates an early prediction in order to achieve
a more aggressive treatment. Most of the deaths reported
after the ﬁrst weeks are due to secondary pancreatic infection
and necrosis [12, 18]. Some authors support that systematic
inﬂammatory response may occur even in the absence of
pancreatic necrosis [7].
Already from the decade of 1980s staging of the severity
of acute pancreatitis using serum criteria was employed [1–
3]. Many clinical trials have employed the use of either
cytokines [4, 5, 8, 9, 11]o rs e r u ma m y l o i dAa n dp r o -
calcitonin (PCT) [11–15] as prognosticators of the severity
of acute pancreatitis. Many authors suggest that PCT may
accurately predict infected pancreatic necrosis. Other studies
over the last few years have suggested that serum levels of
interleukins and TNF-α may be used to identify patients who
are prone to develop local or systemic complications and
were compared with CRP which has been employed in the
prediction of severity of acute pancreatitis. [4, 7–11]. Early
identiﬁcation of such patients could lead to a more intensive
management that would result to a decreased morbidity and
mortality of that potentially fatal disease [4, 7–11].
In the present study, we identiﬁed signiﬁcantly higher
serumlevelsofIL-8inpatientswithsevereacutepancreatitis,
compared to patients with mild or moderate disease. On
admission, mean plasma levels of neither IL-8 nor TNF-
α and CRP showed any signiﬁcant diﬀerence between two
groups but on day 2, signiﬁcantly higher values for IL-8 were
observed on the group of patients with severe pancreatitis.
On the third day, the statistical diﬀerence between the two
groups was continued for the IL-8 levels. TNF-α and CRP
levels did not show any signiﬁcant diﬀerence between the
two groups even in the latest measurement (7th day). In
all patients of the mild group resolution occurred with
supportive treatment within less than one week and no local
or systemic complications were identiﬁed. On the contrary,
the majority of patients in the severe group developed
several either serious (ARDS, MODS, septic shock, pancre-
atic necrosis) or less important complications (3 patients
developed only mild peripancreatic ﬂuid collections without
the evidence of a pseudocyst formation). Three patients were
transferred to the ICU due to multiorgan dysfunction and
one of them who underwent multiple surgical interventions
due to recurrent pancreatic necrosis eventually died.
The highest sensitivity and diagnostic accuracy for IL-8
was observed on the second day. This statistically signiﬁcant
diﬀerence suggests that serum IL-8 levels may be a superior
marker for the early prediction of severe disease comparing
to clinical criteria which have a limited prognostic value.
We believe that the persistence of high levels of IL-8
levels during the ﬁrst week of severe acute pancreatitis may
be related to the development of late local and systemic
complications or its progression to chronic pancreatitis.
TNF-α is known to stimulate the production of several
cytokines including IL-8 and propagate the cascade of
phenomena in severe sepsis [4]. Nevertheless, our study did
notdemonstratearoleofTNF-αasapredictivemarkerofthe
severity of acute pancreatitis. Moreover, although CRP was
elevated in patients with extensive pancreatic necrosis with
bacterial colonization and abscess formation, it did not diﬀer
signiﬁcantly from mild cases.
The aim of our study was to investigate the correlation of
cytokines with the severity and prognosis of acute pancreati-
tis.Ourﬁndingssuggestthepivotalroleofinterleukinstothe
progression of pancreatic injury to systemic inﬂammation.
Since the development of multiorgan failure decreases
dramatically the prognosis in acute pancreatitis patients, it
is of paramount importance to promptly identify high-risk
patients. Measurement and followup of IL-8 serum levels
seems to be an accurate method in order to assess the
extent and persistence of the inﬂammatory process that can
contributetoanearlyandmoreaccuratemanagementofthis
fragile patient group.
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